TNFSF11 and rheumatoid arthritis: A double-blind randomized controlled trial showed that treatment with the anti-RANKL antibody, denosumab, significantly inhibited the progression of joint destruction and was well tolerated, which is expected to become the clinical treatment for RA (283).